Tagging the Trash: Turnover of Toxic Huntingtin
⏱️ 5 min read | A recent study suggests that strengthening the brain’s own clean-up system could slow Huntington’s disease. Read more
Prilenia’s Application for European Approval of Pridopidine Withdrawn
⏱️ 5 min read | Prilenia’s application for European approval of pridopidine was quietly withdrawn 6 months ago, in November 2025, after the EMA had already recommended refusing the drug. Here’s what happened, and why you’re only hearing about it now. Read more
The Great Care Conundrum: What “Good” Care Looks Like in Huntington’s Disease
⏱️8 min read | What does “good care” look like in Huntington’s Disease? A new Dutch study asked familial and professional caregivers, and uncovered how differently it’s experienced in practice. Read more
A Second Path: uniQure Plans Regulatory Filing for AMT-130 in the UK
⏱️ 6 min read | While the US regulatory path for AMT-130 remains complicated, uniQure announced plans to seek approval for its HD gene therapy in the UK. Here’s what that means, and what might be to come. Read more
Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam
⏱️10 min read | PTC Therapeutics shared 2-year data for votoplam, a daily HTT-lowering pill. Stage 2 participants showed up to 52% slowing of disease progression. Here’s what the data show, what’s still missing, and the roll out of the Phase 3 trial. Read more
EN 
ES 
IT 
DE 
FR 